Consistent with the weight-reducing profile of GLP-1 receptor agonists, efpeglenatide, developed for weight reduction in individuals with obesity, has been shown to induce weight loss of approximately 6%–7% in patients with T2DM (Gerstein et al., 2021). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.